UK bioinformatics SME providing cloud genomic analysis platforms for cancer research and in silico clinical trials.
Seven Bridges Genomics is a commercial bioinformatics company that provides a cloud-based platform for genomic data analysis, enabling research teams to run large-scale sequencing pipelines and interpret complex genomic datasets without building their own computational infrastructure. Their core expertise lies in cancer genomics — specifically analysing somatic mutations, tumour evolution, and single-cell sequencing data — making them a specialist technology partner for oncology research consortia. In EU projects they contributed as a third-party platform provider rather than a primary researcher, supplying computational tools and workflows to consortia studying tumour phylogeny, metastasis, and circulating tumour cells. They also supported in silico drug-tracing work in the cardiac disease domain (SILICOFCM), demonstrating applicability beyond oncology.
CONTRA (Computational ONcology TRaining Alliance) lists somatic evolution, tumour phylogeny, circulating tumour cells, and single-cell sequencing as core keywords, directly mapping to Seven Bridges' platform capabilities.
Participation in both CONTRA and SILICOFCM as a third party indicates they supply computational infrastructure rather than conducting primary wet-lab research.
SILICOFCM (in silico trials for sarcomeric protein mutations causing familial cardiomyopathy) demonstrates computational modelling capabilities extending beyond oncology.
Single cell sequencing is explicitly listed among CONTRA's core keywords, reflecting Seven Bridges' known platform capabilities for single-cell RNA and DNA analysis pipelines.
Both H2020 projects began in 2018, so temporal evolution within this dataset is limited. The available keyword data — concentrated entirely in the first half of the project timeline — centres on tumour biology: somatic evolution, tumour phylogeny, cancer metastasis, and single-cell sequencing. The second-half keyword record is empty, most likely because SILICOFCM (their parallel contribution) focused on cardiac disease modelling with no associated keywords recorded in CORDIS. Based on this data alone, no meaningful shift in focus can be confirmed; the profile remains consistently centred on computational biology for disease research.
With only two projects sharing the same start year and no recorded recent-period keywords, the data does not support a directional trend claim; future collaborators should treat Seven Bridges as a stable computational genomics infrastructure provider rather than an organisation actively pivoting to new areas.
Seven Bridges never led an H2020 project — both contributions were as a third party, meaning they provided tools or platform access under the umbrella of consortia led by others. Despite this supporting role, they connected with 32 distinct partners across 14 countries through only two projects, indicating participation in large, multi-national research networks rather than small bilateral partnerships. This pattern suggests they are sought out specifically for their platform capabilities and slot naturally into the technology-provider role within diverse consortia.
Across two projects, Seven Bridges reached 32 unique consortium partners in 14 countries — a notably broad footprint for an organisation with no direct project leadership. This wide reach reflects the large consortia typical of MSCA-ITN and RIA schemes, where platform providers serve many end-user research groups simultaneously.
As a commercial bioinformatics platform company rather than an academic group, Seven Bridges brings production-grade, scalable cloud infrastructure that most university partners in genomics consortia cannot self-build. Their value in EU projects is not discovery research but the computational backbone — reproducible pipelines, data management at scale, and interoperability — that makes large multi-centre genomic studies tractable. For a consortium building around cancer genomics or rare disease modelling, they offer a mature commercial tool paired with credibility from prior EU research participation.
